Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2016 Feb;14(2):153-62.

Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.

Author information

1
From Fox Chase Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Huntsman Cancer Institute at the University of Utah; UCSF Helen Diller Family Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; FORCE-Facing Our Risk of Cancer Empowered; Dana-Farber/Brigham and Women's Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Colorado Cancer Center; Stanford Cancer Institute; The University of Texas MD Anderson Cancer Center; UC San Diego Moores Cancer Center; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; Moffitt Cancer Center; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; University of Washington Medical Center/Seattle Cancer Care Alliance; Roswell Park Cancer Institute; City of Hope Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Mayo Clinic Cancer Center; Vanderbilt-Ingram Cancer Center; and National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making. These NCCN Guidelines Insights summarize major discussion points of the 2015 NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meeting. Major discussion topics this year included multigene testing, risk management recommendations for less common genetic mutations, and salpingectomy for ovarian cancer risk reduction. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer.

PMID:
26850485
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center